2bFVIII gene therapy (Medical College of Wisconsin)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name2bFVIII gene therapy (Medical College of Wisconsin)
Drug Alias NameCD34+PBSC autologous hematopoietic stem cell-based 2bFVIII gene therapy (Medical College of Wisconsin)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCoagulation factor VIII stimulants
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Medical College Of Wisconsin Nonprofit
China Registration ClassN/A

Develop Information

Active CompaniesThe Medical College Of Wisconsin Nonprofit
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A